MECHANISMS OF ACTION
作用机制
基本信息
- 批准号:6655170
- 负责人:
- 金额:$ 18.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2003-08-31
- 项目状态:已结题
- 来源:
- 关键词:analgesics bradycardia cardiovascular function drug adverse effect drug metabolism embryo /fetus drug adverse effect endogenous opioid estrogens guinea pigs hormone regulation /control mechanism muscle contraction neural transmission opioid receptor parasympathetic nervous system peptide analog pharmacokinetics pregnancy progesterone sheep stimulant /agonist sympathetic nervous system synthetic peptide vagus nerve
项目摘要
This new component was developed in response to a perceived need to focus
additional experiments on exploring mechanisms that will improve our
understanding of systemic opioid agonist actions in 3 areas: the role of
peripheral opioid receptors, the non opioid effects of delta-selective
agonists, and clinically relevant side effects of a promising agonist. The
goal of this component is to identify the mechanism(s) which underlie the
physiological responses observed following iv bolus administration of
selective mu and delta opioid peptide analogs that have been identified in
the pharmacodynamic studies conducted in Component 3. Three specific
quests are asked in this proposal. First, how are the cardiovascular
responses to iv DALDA (H-Tyr-Arg-Phe-Lys) mediated? Second, are the
immediate cardiovascular responses to iv DELT (H-Tyr-D-Ala-Phe-Asp-Val-
Val-Gly-NH/2) the result of direct myocardial contractility or are they
vagal in origin? Third, are the pregnancy-associated changes in the
magnitude of the cardiovascular responses to DALDA and DELT mediated by a
change in either estrogen and/or progesterone levels? The specific aims
are: 1) determine if the pressor effect of iv DALDA is due to elevated
cardiac output or increased peripheral vascular resistance; 2) determine
if the cardiovascular effects of iv DALDA are mediated by enhanced
sympathetic activity or decrease parasympathetic activity or decrease
parasympathetic activity; 3) determine if the bradycardia to DELT is
mediated by vagal stimulation; 4) determine the influence of estrogen and
progesterone on the cardiovascular effects of DALDA and DELT; 5) determine
if DALDA has direct positive inotropic and chronotropic action in the hear
and/or whether DALDA alters vagal or sympathetic nerve transmission to the
heart; 6) determine if DELT has direct negative chronotropic and inotropic
action in the heart and/or whether DELT increases vagal nerve transmission
to the heart; 7) determine the role of estrogen and progesterone in
mediating the effects of pregnancy on the cardiac effects of DALDA and
DELT. A combination of in vivo (chronically-instrumented sheep model; aims
1-4) and in vitro (isolated perfused guinea pig heart; aims 5-7)
approaches will be used in this project. These specific aims will be
carried out jointly by Dr. Clapp ( in vivo studies) and Dr. Szeto (in
vitro studies) in their respective laboratories. We feel that
understanding in these areas is necessary to ensure safety and identify
important structure-function relationships for future drug development.
这一新组件是为了响应人们对聚焦的需求而开发的
关于探索机制的额外实验将改善我们的
了解全身性阿片类激动剂在3个领域的作用:
外周阿片受体、选择性增量非阿片效应
激动剂,以及一种有前景的激动剂的临床相关副作用。这个
这一部分的目标是确定构成
静脉推注给药后的生理反应观察
选择性Mu和Delta阿片肽类似物,已在
第三部分进行的药效学研究。
在这个提案中,任务被提了出来。首先,心血管疾病怎么样?
静脉注射DALDA(H-Tyr-Arg-Phe-Lys)介导的反应?第二,是
静注DELT的即刻心血管反应(H-Tyr-D-Ala-Phe-Asp-Val.
Val-Gly-NH/2)是直接心肌收缩的结果还是它们
起源于迷走神经?第三,是否与怀孕相关的变化
A介导的DALDA和DELT对心血管反应的幅度
雌激素和/或黄体酮水平的变化?具体目标
1)确定静脉注射达尔达的升压效应是否由升压引起
心输出量或外周血管阻力增加;2)确定
如果静脉注射达尔达的心血管效应是通过增强
交感神经活动或副交感神经活动减少或减少
副交感神经活动;3)确定DELT的心动过缓是否
由迷走神经刺激介导;4)测定雌激素和
孕酮对DALDA和DELT心血管效应的影响;5)测定
如果达尔达在心脏有直接的正性变力和变时性作用
和/或Dalda是否改变迷走神经或交感神经传递到
心脏;6)确定DELT是否具有直接负性变时性和变力性
心脏活动和/或DELT是否增加迷走神经传递
对心脏的作用;7)确定雌激素和孕激素在
探讨妊娠对达尔达心脏效应的影响
Delt.体内(慢性仪器化绵羊模型;目标)的组合
1-4)和体外(离体豚鼠心脏;AIMS 5-7)
在这个项目中将使用各种方法。这些具体目标将是
由Clapp博士(体内研究)和司徒华博士(在
体外研究)。我们觉得
对这些领域的了解对于确保安全和确定
未来药物开发的重要结构-功能关系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAZEL H SZETO其他文献
HAZEL H SZETO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HAZEL H SZETO', 18)}}的其他基金
Mitoprotective and antioxidant peptides for DM treatment
用于 DM 治疗的线粒体保护和抗氧化肽
- 批准号:
7027847 - 财政年份:2005
- 资助金额:
$ 18.07万 - 项目类别:
Mitoprotective and antioxidant peptides for DM treatment
用于 DM 治疗的线粒体保护和抗氧化肽
- 批准号:
7125021 - 财政年份:2005
- 资助金额:
$ 18.07万 - 项目类别:
Cell-Permeable Peptides for Mitochondrial Protection
用于线粒体保护的细胞渗透肽
- 批准号:
6763598 - 财政年份:2004
- 资助金额:
$ 18.07万 - 项目类别:
Cell-Permeable Peptides for Mitochondrial Protection
用于线粒体保护的细胞渗透肽
- 批准号:
6873062 - 财政年份:2004
- 资助金额:
$ 18.07万 - 项目类别:
MATERNAL/FETAL PHARMACOKINETICS AND PHARMACODYNAMICS
母体/胎儿药代动力学和药效学
- 批准号:
6655169 - 财政年份:2002
- 资助金额:
$ 18.07万 - 项目类别:
MATERNAL/FETAL PHARMACOKINETICS AND PHARMACODYNAMICS
母体/胎儿药代动力学和药效学
- 批准号:
6495088 - 财政年份:2001
- 资助金额:
$ 18.07万 - 项目类别:
相似海外基金
Electrical remodeling of atrial myocyte induced by chronic inflammation or bradycardia and its role in the atrial fibrillation.
慢性炎症或心动过缓诱导的心房肌细胞电重塑及其在心房颤动中的作用。
- 批准号:
23K06340 - 财政年份:2023
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ganglionated plexus ablation in sinus node dysfunction: autonomic modulation and suppressive effect of bradycardia
窦房结功能障碍的神经节丛消融:自主神经调节和心动过缓的抑制作用
- 批准号:
23K08264 - 财政年份:2023
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Optimizing Chest Compressions for Bradycardia during Neonatal Resuscitation
新生儿复苏期间针对心动过缓优化胸外按压
- 批准号:
10185827 - 财政年份:2021
- 资助金额:
$ 18.07万 - 项目类别:
Optimizing Chest Compressions for Bradycardia during Neonatal Resuscitation
新生儿复苏期间针对心动过缓优化胸外按压
- 批准号:
10397630 - 财政年份:2021
- 资助金额:
$ 18.07万 - 项目类别:
Optimizing Chest Compressions for Bradycardia during Neonatal Resuscitation
新生儿复苏期间针对心动过缓优化胸外按压
- 批准号:
10617667 - 财政年份:2021
- 资助金额:
$ 18.07万 - 项目类别:
Identification of neural pathway involving innate fear-induced hypothermia and bradycardia
涉及先天恐惧引起的体温过低和心动过缓的神经通路的识别
- 批准号:
18K06515 - 财政年份:2018
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of key molecules for exercise-induced bradycardia: involvement of oxidative stress in functional regulation of the cardiac pacemaker
运动诱发心动过缓关键分子的研究:氧化应激参与心脏起搏器的功能调节
- 批准号:
18K15017 - 财政年份:2018
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mathematical analysis of arrhythmogenesis for bradycardia
心动过缓心律失常发生的数学分析
- 批准号:
17H04018 - 财政年份:2017
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Slowing the pace: Cellular and Molecular Mechanisms of Bradycardia in the Anoxic Turtle (Trachemys scripta)
放慢速度:缺氧龟(Trachemys scripta)心动过缓的细胞和分子机制
- 批准号:
1557818 - 财政年份:2016
- 资助金额:
$ 18.07万 - 项目类别:
Standard Grant
Tetrahydrobiopterin-deficiency causes hypertension with fluctuation, bradycardia and priapism.
四氢生物蝶呤缺乏会引起波动性高血压、心动过缓和阴茎异常勃起。
- 批准号:
16K08561 - 财政年份:2016
- 资助金额:
$ 18.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)